GSK agreed to acquire global rights to a preclinical trispecific T-cell engager from Chimagen Biosciences in a deal worth up to $750 million. The company plans to develop the asset for multiple myeloma, with a Phase I trial expected to start in 2027. The arrangement includes an undisclosed upfront payment and potential success-based development and commercial milestones. The move marks GSK’s second transaction with Chimagen within two years, extending a broader China-focused oncology innovation strategy that also spans immunology, respiratory disease, and cardiometabolic programs.